Tuesday, April 29, 2025

Latest

Mind Cure Receives Health Canada Approval For Sale Of Moonbeam Mushroom Products

Mind Cure Health (CSE: MCUR) has received the required authorizations from Health Canada for its functional mushroom products to begin to be sold within the country. The company has seen its branded Moonbeam Mushrooms products issued Natural Product Numbers the agency, enabling for the sale of the products at retailers.

The authorizations put the product line ahead of many competitors within the supplement and nutrition space whom often skip the task of receiving Health Canada compliance. Having the approval from the agency will provide additional transparency to consumers, while providing evidence that the products are in fact considered natural supplements.

The Moonbeam Mushrooms product line consists of three offerings, each of which is offered in the form of powder and capsules. The products are focused on different functional mushrooms, including Lion’s Mane, Reishi, and Turkey Tail. Further, they have been marked as being non-GMO, vegan, organic, free of soy as well as gluten. New product offerings from the firm are currently being investigated as well, in the fields of nootropics, psychoactive products and psychedelic substances.

A timeline for products to hit retailers was not provided.

Mind Cure Health last traded at $0.55 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024

Related News

Mind Cure Health Appoints Rob Hill To Board Of Directors

Mind Cure Health (CSE: MCUR) this morning announced the appointment of Rob Hill to the...

Monday, February 22, 2021, 09:12:53 AM

Mind Cure Health Focuses On Research Into Psychedelics For Traumatic Brain Injury

Mind Cure Health (CSE: MCUR) as of this morning has seen the transition of one...

Wednesday, February 17, 2021, 07:27:04 AM

Mindcure Ends Fiscal Q1 2022 With $15.6 Million Cash & Cash Equivalents, $2.8 Million Net Loss

Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended...

Wednesday, October 27, 2021, 10:41:00 AM

Mind Cure Health Begins Research Into Psychedelic Compounds

Mind Cure Health (CSE: MCUR) has reached a milestone, with the company this morning announcing...

Tuesday, December 8, 2020, 08:04:33 AM

Mind Cure Closes $3.6 Million Oversubscribed Financing

Mind Cure Health (CSE: MCUR) reported midday today that it has closed its non-brokered private...

Thursday, November 19, 2020, 04:28:12 PM